

CT:VQ™ deployed at Mayo Clinic

25 March 2026

Highlights

- Mayo Clinic, consistently ranked the number one hospital in the United States, deploys CT:VQ™ for ventilation and perfusion analysis
- Mayo Clinic becomes the sixth leading U.S. Academic Medical Center (AMC) to adopt CT:VQ™, following Stanford, Cleveland Clinic, UC San Diego Health, University of Chicago Medicine, and University of Miami
- Initial deployment will support clinical workflow integration and build clinician familiarity with CT:VQ™'s advanced capabilities, with potential to expand to full commercial terms
- Mayo Clinic's deployment represents one of the most significant institutional endorsements to date, reinforcing CT:VQ™'s growing reputation among the elite healthcare institutions in the U.S.
- Six leading Academic Medical Center deployments achieved within approximately seven months of FDA clearance, demonstrating extraordinary commercial momentum

Melbourne, Australia, 25 March 2026 – 4DMedical Limited (ASX: 4DX, “4DMedical” or the “Company”), a global leader in respiratory imaging technology, today announces that Mayo Clinic has initiated deployment of CT:VQ™ for ventilation and perfusion analysis.

CT:VQ™ deployment at Mayo Clinic

Mayo Clinic (“Mayo”), consistently ranked the number one hospital in the United States, has entered into an agreement for the use of CT:VQ™. Under the arrangement, Mayo will utilise CT:VQ™ for ventilation and perfusion analysis, enabling Mayo’s clinical teams to build familiarity with the technology’s advanced diagnostic outputs, and to assess its application across a range of clinical use cases.

Mayo Clinic’s decision to deploy CT:VQ™ represents one of the most significant institutional endorsements to date for 4DMedical’s breakthrough respiratory imaging technology. As a globally respected and influential healthcare institution, Mayo’s use of CT:VQ™ sends a powerful signal to the broader U.S. healthcare market about the clinical relevance and transformative potential of the technology.

The deployment follows the successful commercial rollout of CT:VQ™ at five leading U.S. Academic Medical Centers: Stanford, Cleveland Clinic, UC San Diego Health, University of Chicago Medicine, and University of Miami. Mayo’s engagement extends 4DMedical’s footprint to six of the nation’s most prestigious healthcare institutions, further reinforcing the Company’s strategy of establishing CT:VQ™ at elite reference sites to drive broader market adoption.

Building on extraordinary commercial momentum

In approximately seven months since FDA clearance in September 2025, 4DMedical has now secured deployments at six of America’s most respected Academic Medical Centers. The pace of institutional adoption is unprecedented and reflects the compelling clinical value proposition of CT:VQ™: eliminating the need for radioisotope and contrast administration, providing superior image resolution compared to nuclear medicine, seamlessly integrating into existing CT imaging workflows, and enabling access to reimbursement pathways that support sustainable clinical adoption.



While the initial 90-day agreement is not financially material, Mayo Clinic's deployment of CT:VQ™ is strategically significant. Mayo's influence on clinical practice, treatment guidelines, and technology adoption across U.S. and global health systems is unparalleled. As Mayo's clinicians integrate CT:VQ™ into their workflows and develop confidence in its application across pulmonary and cardiothoracic use cases, the institution has the potential to become a powerful reference site in 4DMedical's growing network, serving as a game-changing catalyst for broader commercial deployment.

Combined with the Philips distribution partnership and 4DMedical's growing commercial pipeline, the Mayo deployment further strengthens the Company's position as it works to establish CT:VQ™ as the new standard of care in ventilation-perfusion imaging.

4DMedical MD/CEO and Founder Andreas Fouras said:

Mayo Clinic is, unquestionably, one of the most respected healthcare institutions in the world. Their decision to deploy CT:VQ™ is a landmark moment for 4DMedical and a powerful testament to the clinical significance of our technology.

In just seven months since FDA clearance we have established CT:VQ™ at six of America's leading AMCs: Stanford, University of Miami, Cleveland Clinic, UC San Diego Health, University of Chicago Medicine, and now Mayo Clinic. No other technology in our space has achieved this level of clinical adoption in such a short timeframe.

Mayo's deployment is uniquely significant. When the world's number one hospital chooses to use your technology, it sends the strongest possible signal to the entire U.S. healthcare market about the clinical value and readiness of CT:VQ™. Combined with our existing network of elite AMC reference sites, and the Philips partnership, we are building an unassailable platform for CT:VQ™ adoption.

CT:VQ™ continues to accelerate. Our sales pipeline has never looked stronger, and I look forward to sharing further progress soon.

–ENDS–

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate

Investor Relations

investor.relations@4dmedical.com

Administration

Company Secretary

companysecretary@4dmedical.com

Media Enquiries

Julia Maguire

julia@thecapitalnetwork.com.au

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company revolutionising respiratory care with advanced imaging and artificial intelligence. Its patented **XV Technology®** transforms standard scans into rich, functional insights that allow physicians to detect, diagnose, and monitor lung disease earlier and with greater precision.

4DMedical's expanding software portfolio includes the FDA-cleared **XV Lung Ventilation Analysis Software (XV LVAS®)**, **CT LVAS™**, and the ground-breaking **CT:VQ™** solution designed to set new benchmarks in cardiothoracic imaging by combining ventilation and perfusion analysis.



Delivered seamlessly through a Software-as-a-Service (SaaS) model, 4DMedical's solutions integrate into existing hospital infrastructure, enhancing physician productivity and enabling more personalised patient care. With the addition of advanced AI capabilities from its 2023 acquisition of **Imbio**, 4DMedical continues to push the boundaries of medical imaging to redefine how respiratory disease is understood and treated worldwide.

Learn more at www.4dmedical.com

For personal use only